S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
OTCMKTS:MEOBF

Mesoblast - MEOBF Stock Forecast, Price & News

$0.74
0.00 (0.00%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.74
▼
$0.74
50-Day Range
$0.57
▼
$0.74
52-Week Range
$0.44
▼
$0.86
Volume
N/A
Average Volume
1,400 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MEOBF stock logo

About Mesoblast (OTCMKTS:MEOBF) Stock

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MEOBF Stock News Headlines

January 11, 2023 | finance.yahoo.com
Mesoblast Limited (MEOBF) Stock Historical Prices & Data - Yahoo Finance
September 29, 2022 | reuters.com
MESO.O - Mesoblast limited (ADR) | Stock Price & Latest News | Reuters
March 22, 2023 | Investing Daily (Ad)
How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
September 29, 2022 | investing.com
Mesoblast Teva Starts
September 1, 2022 | seekingalpha.com
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
September 1, 2022 | seekingalpha.com
Mesoblast Limited 2022 Q4 - Results - Earnings Call Presentation
May 25, 2022 | markets.businessinsider.com
MindMed Appoints Schond L. Greenway As CFO
May 25, 2022 | benzinga.com
Mesoblast (OTC:MEOBF), Short Interest Report
March 22, 2023 | Investing Daily (Ad)
How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
May 25, 2022 | benzinga.com
Mesoblast (OTC:MEOBF), Earnings Estimates, EPS, and Revenue
April 29, 2022 | seekingalpha.com
Mesoblast reports FQ3 results
March 28, 2022 | fool.com
Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript
August 31, 2021 | markets.businessinsider.com
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
August 24, 2021 | finance.yahoo.com
Loss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-Term
July 19, 2021 | finance.yahoo.com
Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
July 18, 2021 | benzinga.com
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
July 15, 2021 | finance.yahoo.com
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
July 1, 2021 | finance.yahoo.com
Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain
June 30, 2021 | finance.yahoo.com
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
June 25, 2021 | finance.yahoo.com
Is Mesoblast (ASX:MSB) Using Debt Sensibly?
June 2, 2021 | finance.yahoo.com
Operational Highlights and Financial Results for the Period Ended March 31, 2021
June 2, 2021 | markets.businessinsider.com
Mesoblast Corporate Update and Financial Results Webcast
May 25, 2021 | finance.yahoo.com
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
May 3, 2021 | finance.yahoo.com
Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?
March 30, 2021 | finance.yahoo.com
Mesoblast Operational Highlights and Upcoming Milestones
March 29, 2021 | finance.yahoo.com
Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board
February 10, 2021 | finance.yahoo.com
Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
See More Headlines
Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MEOBF
CUSIP
N/A
CIK
1345099
Web
www.mesoblast.com
Phone
(139) 639-6036
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Silviu Itescu
    Chief Executive Officer, MD & Executive Director
  • Dagmar Rosa-Bjorkeson
    Chief Operating Officer
  • Andrew Chaponnel
    Chief Financial Officer & Head-Finance
  • Eric A. Rose
    Executive Director & Chief Medical Officer
  • Michael Schuster
    Head-Pharma Partnering

Key Competitors

View All Competitors













MEOBF Stock - Frequently Asked Questions

How have MEOBF shares performed in 2023?

Mesoblast's stock was trading at $0.5749 at the beginning of the year. Since then, MEOBF stock has increased by 28.5% and is now trading at $0.7389.
View the best growth stocks for 2023 here.

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest in February. As of February 15th, there was short interest totaling 2,481,700 shares, an increase of 591.7% from the January 31st total of 358,800 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Mesoblast's Short Interest.

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

How do I buy shares of Mesoblast?

Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $0.74.

How can I contact Mesoblast?

Mesoblast's mailing address is 55 Collins Street, Melbourne, Victoria (VIC). The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036.

This page (OTCMKTS:MEOBF) was last updated on 3/22/2023 by MarketBeat.com Staff